ValuEngine upgraded shares of Insys Therapeutics (NASDAQ:INSY) from a buy rating to a strong-buy rating in a research note published on Thursday.
Several other equities research analysts also recently issued reports on the stock. Piper Jaffray Companies set a $4.00 price objective on shares of Insys Therapeutics and gave the stock a sell rating in a research note on Saturday, August 11th. Jefferies Financial Group restated a buy rating and issued a $10.00 price objective on shares of Insys Therapeutics in a research note on Friday, August 10th. Royal Bank of Canada restated a buy rating and issued a $9.00 price objective on shares of Insys Therapeutics in a research note on Thursday, August 9th. Finally, Zacks Investment Research downgraded shares of Insys Therapeutics from a hold rating to a sell rating in a research note on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Insys Therapeutics currently has a consensus rating of Hold and an average target price of $7.67.
Shares of Insys Therapeutics stock traded down $0.04 during midday trading on Thursday, hitting $8.95. The company had a trading volume of 447,900 shares, compared to its average volume of 903,487. The company has a market cap of $618.46 million, a price-to-earnings ratio of -18.27 and a beta of 1.65. Insys Therapeutics has a 1-year low of $4.88 and a 1-year high of $14.00.
Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.17). The company had revenue of $23.47 million during the quarter, compared to analyst estimates of $25.91 million. Insys Therapeutics had a negative return on equity of 130.43% and a negative net margin of 238.31%. The company’s revenue was down 44.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.03 EPS. On average, analysts anticipate that Insys Therapeutics will post -1.24 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of INSY. JPMorgan Chase & Co. boosted its stake in Insys Therapeutics by 303.5% during the first quarter. JPMorgan Chase & Co. now owns 25,624 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 19,273 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Insys Therapeutics by 47.4% during the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after buying an additional 10,001 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Insys Therapeutics by 33.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 126,335 shares of the specialty pharmaceutical company’s stock worth $915,000 after buying an additional 31,840 shares in the last quarter. BlackRock Inc. boosted its stake in Insys Therapeutics by 7.9% during the second quarter. BlackRock Inc. now owns 2,637,505 shares of the specialty pharmaceutical company’s stock worth $19,096,000 after buying an additional 193,740 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new stake in Insys Therapeutics during the second quarter worth $131,000. Hedge funds and other institutional investors own 18.02% of the company’s stock.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Recommended Story: 52-Week High/Low
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.